Cultural upbringing gives context to sexual dysfunction but does not make the diagnosis, according to Sameena Rahman, MD, FACOG.
|Articles|September 4, 2014
Postmenopausal status ups odds of malignant endometrial polyps (VIDEO)
Mary Leuchars, MD, discusses the higher prevalence of malignant or pre-malignant polyps in women undergoing recession of indometrial polyps, who are also post-menopausal and who have abnormal uterine bleeding, as reported in the journal Obstetrics & Gynecology.
Advertisement
Mary Leuchars, MD, discusses the higher prevalence of malignant or pre-malignant polyps in women undergoing recession of indometrial polyps, who are also post-menopausal and who have abnormal uterine bleeding, as reported in the journal
This video is part of the
Video provided by:
Advertisement
Related to this article
In September, the FDA accepted an extended duration sNDA for the IUD with a decision expected in Q2 2027.
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
FDA removes boxed warnings from 3 more menopausal hormone therapy products
3
Chrisandra Shufelt, MD, on cardiovascular risk assessment and menopause care
4
Matthew Nudy, MD, on estrogen and the cardiovascular system
5